Glaxo And Novartis Scratch Each Other’s Back With Consumer Product JV
This article was originally published in The Tan Sheet
The combination of the firm’s consumer portfolios will create the No. 1 global OTC business, Duetsche Bank analysts say. GSK estimates OTC sales from JV will reach $5.72 billion, representing more than half of the $10 billion in overall annual sales anticipated for the consumer health product JV.